Picture of Neuroscientific Biopharmaceuticals logo

NSB Neuroscientific Biopharmaceuticals Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapContrarian

Momentum

Relative Strength (%)
1m+2.64%
3m+36%
6m-32.61%
1yr-32.41%
Volume Change (%)
10d/3m+68%
Price vs... (%)
52w High-62.14%
50d MA+12.67%
200d MA-23.16%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.01
Price to Tang. Book2.27
Price to Free Cashflow731.3
Price to Sales1.95
EV to EBITDA5.12

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital20.35%
Return on Equity23.29%
Operating Margin19.7%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Neuroscientific Biopharmaceuticals EPS forecast chart

Profile Summary

NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
November 14th, 2002
Public Since
July 27th, 2018
No. of Shareholders
1,407
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
144,604,870

NSB Share Price Performance

Upcoming Events for NSB

Full Year 2024 NeuroScientific Biopharmaceuticals Ltd Earnings Release

Similar to NSB

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Algorae Pharmaceuticals logo

Algorae Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

FAQ